Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
| Autor: | Holger Rumpold, Sonja Burgstaller, Günther Gastl, Veronika Buxhofer-Ausch, Thamer Sliwa, Klaus Geissler, Maria-Theresa Krauth, Heinz Gisslinger, Peter Krippl, Albert Wölfler, Felix Keil, Thomas Melchardt, Andreas L. Petzer, Stefan Wöhrer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Ruxolitinib Consensus 03 medical and health sciences 0302 clinical medicine Nitriles Medicine Humans Intensive care medicine Adverse effect Myelofibrosis Retrospective Studies Modalities Janus kinase 2 biology Post-Essential Thrombocythemia Myelofibrosis business.industry Correction General Medicine medicine.disease Europe Therapy management Pyrimidines Primary Myelofibrosis 030220 oncology & carcinogenesis Austria biology.protein Pyrazoles business 030215 immunology medicine.drug |
| Zdroj: | Wiener klinische Wochenschrift. 130(17-18) |
| ISSN: | 1613-7671 |
| Popis: | The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. Since its introduction, the expertise of prescribing doctors with respect to ruxolitinib function, efficacy and adverse effects has consistently been augmented, resulting in therapy modalities that are better tailored to individual patients as well as in increased safety of the treatment. The present consensus on ruxolitinib therapy management has been elaborated by Austrian experts in myeloproliferative neoplasms in line with international treatment guidelines. Our recommendations aim to contribute to an improved management of patients with myelofibrosis treated with ruxolitinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink